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Abstract: Iron and zinc are essential minerals often present in similar food sources. In 
addition to the adverse effects of frank iron and zinc-deficient states, iron insufficiency has 
been associated with impairments in mood and cognition. This paper reviews current 
literature on iron or zinc supplementation and its impact on mood or cognition in  
pre-menopausal women. Searches included MEDLINE complete, Excerpta Medica 
Database (EMBASE), psychINFO, psychARTICLES, pubMED, ProQuest Health and 
Medical Complete Academic Search complete, Scopus and ScienceDirect. Ten randomized 
controlled trials and one non-randomized controlled trial were found to meet the inclusion 
criteria. Seven studies found improvements in aspects of mood and cognition after iron 
supplementation. Iron supplementation appeared to improve memory and intellectual ability 
in participants aged between 12 and 55 years in seven studies, regardless of whether the 
participant was initially iron insufficient or iron-deficient with anaemia. The review also 
found three controlled studies providing evidence to suggest a role for zinc supplementation 
as a treatment for depressive symptoms, as both an adjunct to traditional antidepressant 
therapy for individuals with a diagnosis of major depressive disorder and as a therapy in its 
own right in pre-menopausal women with zinc deficiency. Overall, the current literature 
OPEN ACCESS 
 
Nutrients 2014, 6 5118 
 
indicates a positive effect of improving zinc status on enhanced cognitive and emotional 
functioning. However, further study involving well-designed randomized controlled trials is 
needed to identify the impact of improving iron and zinc status on mood and cognition. 
Keywords: iron deficiency; zinc deficiency; pre-menopausal women; depression; cognition 
 
1. Introduction 
Iron insufficiency, or mild iron deficiency (ID), in the absence of anaemia is defined as depleted iron 
stores. When the absence of iron stores affects erythropoiesis, this reduces haemoglobin (Hb) 
concentration and iron deficiency anaemia (IDA) occurs [1]. ID is the most prevalent single nutrient 
deficiency in the world, affecting not only those in economically developing countries, but also 
individuals in developed countries [2,3]. Pre-menopausal women are at greater risk of ID due to their 
regular menstrual blood loss and elevated iron requirements in pregnancy [4,5]. Iron and zinc are often 
present in similar dietary sources, such as whole-grain cereals, red meats, legumes, seeds and nuts, as 
well as seafood, and deficiencies in iron and zinc often co-occur [6–8]. However, data on the prevalence 
of zinc deficiency are lacking, due to the absence of a biochemical marker of total body zinc status. 
Plasma or serum zinc concentrations, the most widely used indicators of zinc status, are maintained 
within a narrow range (12–15 μmol/L) and require fasting blood samples for a meaningful test [7,9]. 
Hair zinc concentration is often used in combination with plasma zinc to provide a good indication of 
zinc status [10,11]. However, hair zinc alone is better for representing longer-term zinc status. Further, the 
use of hair zinc concentration as an index of zinc status suffers from limited reference data and variations 
due to age, sex, season, hair colour and hair growth rate [12]. Thus, alternative methods have been used to 
estimate zinc deficiency in populations based on reported dietary intake. For example, World Health 
Organization (WHO) [13] used a factorial approach to estimate the average basal and standard zinc 
requirements (i.e., minimum amount of zinc to cover losses in individuals adapted or not adapted to low 
usual dietary intakes of zinc) for population subgroups and then considered issues of zinc bioavailability 
from the typical diet in various regions of the world to derive estimates of the minimal dietary intake of 
zinc that would meet these requirements. Using this approach, WHO [14] estimates that zinc deficiency 
affects around one-third of the world’s population. 
Research suggests that ID is strongly linked to cognition, mood, zinc insufficiency and depression. 
However, the evidence of a causal link though intervention studies is still limited or the results have been 
mixed. Furthermore, there is limited research assessing the effect of increasing the dietary intakes of 
both iron and zinc on markers of mood or cognition. This systematic literature review considers 
randomized controlled trials, investigating the effect of increasing either iron or zinc (either  
though supplementation or dietary methods) on markers of mood or cognition, primarily in  
pre-menopausal women. 
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2. Method 
2.1. Selection Criteria 
2.1.1. Participants 
Participants were required to be adolescent girls and pre-menopausal women between the ages of  
12 and 55 years. Participants were also required to exhibit evidence of either ID or IDA based on Hb 
concentration, Hb plus ferritin or other author-defined evidence of ID or IDA. No restrictions on 
participant levels of zinc deficiency were applied to studies evaluating increased zinc intake; however, 
participants were still required to be females aged between 12 and 55 years. Included studies were 
required to have a sample size larger than 10. Studies with a population younger than 12, or older than 
55 years of age, or that included non-human subjects were also excluded. Studies that included some 
male participants were only included if the results for females were reported separately. 
2.1.2. Types of Studies 
Included studies were intervention, placebo-controlled trials with a control group assessing the effect 
of increasing iron or zinc on markers of mood or cognition. Studies were excluded if they investigated 
an unrelated disorder (e.g., iron/cognition/Alzheimer’s disease). The intervention period had to be at 
least 4 weeks in length, and the effects of the intervention on mood or cognition had to be assessed by a 
recognized assessment tool. 
2.1.3. Outcome Measures 
Domains of cognitive functioning considered relevant for this review included attention, memory, 
learning, psychomotor skills and concentration. The mood domain of predominate focus in this review 
was depression, but also included anxiety, irritability and anger. 
2.2. Identification of Studies 
The original search was conducted in May, 2013 (Appendix 1). Originally, the focus of the review 
planned to include studies that used dietary methods to increase iron or zinc. However, due to a paucity 
of these types of studies, the search terms were modified to capture both dietary intake and oral iron 
supplementation of iron and zinc and to limit research to female participant groups (Appendix 2). 
Electronic searching was conducted using the following databases: ProQuest Health and Medical 
Complete, MEDLINE complete, Excerpta Medica Database (EMBASE), PubMed, psychINFO, 
psychARTICLES, Academic Search complete, Scopus and ScienceDirect between May 2013 and 
August 2013. Key terms (iron) AND (deficien* OR status OR intake OR “dietary intake” OR nutrition*) 
and (zinc) AND (deficien* OR status OR intake OR “dietary intake” OR nutrition*) were searched in 
the title, abstract and keywords and key terms (mood OR affect* OR depress*) and (cognit*), (wom?n 
OR “female”) in the subject. Iron and zinc were searched separately in relation to their effects on mood 
and cognition. The search was not limited by language, but included the use of a “peer review only” 
filter. Articles published between January 1995 and May 2013, were included in the search. The 
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references of identified trials and relevant review articles were examined for eligible studies that may 
have been missed in the original search. 
2.3. Screening Process 
After electronic searching was complete and duplicates removed, titles and keywords were scanned 
for relevance; articles were retrieved if these included a combination of iron and/or zinc and mood and/or 
cognition. Abstracts of the retrieved articles were further screened for relevance, removing papers that 
were reviews or commentaries. Full-text articles were read, and papers not meeting the inclusion criteria 
were removed. 
2.4. Data Extraction 
The data extracted included the year of publication, randomization procedures, allocation 
concealment, blinding, setting, characteristics of participants (e.g., age, country and relevant 
demographics), characteristics of intervention, baseline iron/zinc status data, information regarding 
attrition/dropout rates and length of clinical trials. Furthermore, the characteristics of the main outcome 
measures, analytic methodology and relevant results were extracted for evaluation. Data were extracted 
by the review author and cross-referenced by another author (Linda K. Byrne). 
3. Results 
3.1. Search Results 
A total of 2046 articles were retrieved from database searches, and a further nine were retrieved from 
additional sources (i.e., reference lists; academic colleagues). The titles and abstracts were screened for 
eligibility, and 30 full-text articles were assessed for inclusion. Eleven articles met the criteria for 
inclusion in this review. No articles in a language other than English were retrieved. In total, nine 
randomized controlled trials and two non-randomized controlled trials were included in the review 
(Figure 1). 
3.2. Study Characteristics 
A detailed summary of the study characteristics is included in Table 1. Three studies were conducted 
in the United States [2,15,16]; two were in Poland [17,18], and one study was conducted each in  
Japan [19], India [20], South Africa [21], France [22], Switzerland [19] and New Zealand [23]. 
3.3. Participant Characteristics 
Eight studies included only pre-menopausal women [2,15,16,19,21,22,24]. Three included male 
participants [17,18,20]. Participants of one study included women who were six weeks postpartum [21], 
and two studies included participants that met the Diagnostic Statistical Manual of Mental Disorders—
Fourth Edition Text Revision (DSM-IV-TR) criteria for major depressive disorder (MDD), 
differentiating these two populations from those of the rest of the included studies [17,18]. The sample 
sizes for studies were heterogeneous and ranged from between 20 and 219 participants. 
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Figure 1. Flow chart of how the literature was selected for inclusion. 
 
3.4. Design 
Of the 11 included studies, nine were randomized, placebo-controlled, double-blind  
procedures [2,15–17,19,21–24]. Of the remaining two studies, one was a non-randomized,  
placebo-controlled trial and did not explain the blinding procedure [20], and the other did not explicate 
the allocation process [18]. Three studies looked at the effects of oral iron supplementation on  
cognition only [2,15,23], while three looked at the effects of oral iron supplementation on just  
mood [16,22,24]. A further two assessed both variables as outcomes [20,21]. No studies were found that 
examined the effect of increasing dietary intake of iron and any subsequent effect on mood or cognition. 
Records identified through 
database searching 
(n = 2046) 
Additional records identified 
through other sources 
(n = 9) 
Records after  
duplicates removed 
(n = 1619) 
Titles Screened 
(n = 1619) 
Records Excluded (n = 1416) 
Animals (n = 55) 
Age inappropriate (n=417) 
Confounding Disorder (n = 814) 
Abstracts Screened 
(n = 203) 
Articles excluded (n = 173) 
Reasons for Exclusion, non-research 
article, animal studies, participants 
male only, or out of age range 
Full-text articles assessed  
for eligibility 
(n = 30) 
Studies excluded (n = 19) 
Observational (n = 14) 
Published before 1995 (n = 2) 
Studies included in  
Systematic review 
(n = 11) 
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The iron status of participants varied between the studies, and Table 1 includes further information 
regarding the levels used to determine iron status in each individual study. Three studies included ID, 
IDA treatment and iron-sufficient control groups and examined differences in changes between all three 
groups [2,16,20]. One included participants with only IDA and excluded those with ID [21]. Four studies 
included only participants with ID, but failed to have iron-sufficient control groups [15,22–24]. 
Three intervention studies were found looking at the effects of zinc supplementation and depression. 
One of these looked specifically at the effect of zinc supplementation in depressive symptoms in  
pre-menopausal women [19]. The two papers remaining, focusing on zinc, looked at the effect of using 
zinc supplementation as an adjunct to antidepressant therapy. Additionally, both used participants that 
met the criteria for MDD [17,18]. Similar to the iron studies, no intervention studies were found that 
assessed the effect of dietary zinc on depressive symptoms. Furthermore, the search yielded no results 
for intervention trials that fit the inclusion criteria and that specifically examined the effects of zinc 
supplementation on cognitive functioning. 
3.5. Measures of Cognition 
Outcome measures for cognitive function varied across studies, as did the domain of cognition 
assessed for each study. Most of the included studies measured multiple domains of cognitive 
functioning. These included attention, working memory and other aspects of memory (e.g., short-term 
memory (STM) and long-term memory (LTM)), learning and intellectual abilities. A detailed summary 
of cognitive outcome measures used in each study is described in Table 2. Three of the 11 included 
studies measured aspects of attention [2,15,23]. Five assessed aspects of memory [2,15,20,21,23];  
three assessed intellectual ability [2,20,21], and two assessed learning [2,21]. 
3.6. Measures of Depression 
Outcome measures used to determine depression or depressive symptoms varied considerably 
between studies. A detailed summary of the outcome assessment tools used for each individual study is 
outlined in Table 2. Four studies measured depressive symptoms, pre-/post-intervention [17,18,22,24], 
while a further two assessed general mood state, using subscales of the measures to assess depressive 
symptoms [16,19,20]. One study used a measure that specifically assessed postpartum depression [21]. 
3.7. Analytic Methodology 
Table 2 has a detailed summary of the statistical analyses applied in each study. Eight studies used 
analysis of variance (ANOVA) [2,15–18,20,21]; three used multiple linear regression [15,23,24]; one 
used Pearson’s correlation [16]; and one used a repeated measures analysis of covariance (ANCOVA), 
with intellectual ability (IQ) as a covariate [2]. One further study used Wilcoxon’s sign-ranked test [19] 
to assess differences. 
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Table 1. Characteristic summary of the included studies (N = 11). ID, iron deficiency. 
Study n Population Iron or Zinc Intervention Baseline Iron or Zinc Status 
Study Duration 
and Dropouts 
Outcome Measures 
Bruner et al., 
1996 [15] 
81 
American adolescent 
females, ID only,  
13–18 years  
Daily dose of 1300 mg 
ferrous sulphate, equivalent 
to 260 mg elemental iron 
ID = serum ferritin <12 μg/L, with 
normal haemoglobin (Hb) 
8 weeks  
8 dropouts 
The Brief Test of Attention, 
Symbol Digits Modalities.  
The Visual Search and Attention 
Test, The Hopkins Verbal  
Learning Test 
IDA ≤ Hb 115 g/L for African 
American girls or <Hb 120 g/L for 
caucasian girls 
Beard et al., 
2005 [21] 
95 
South African mothers, 
18–30 years 
Daily dose of 125 mg 
ferrous sulphate to  
anaemic mothers 
IDA = Hb 90–115 g/L + 2 of the 
following: mean corpuscular  
volume <80 femtoliters (fL),  
transferrin saturation <15%,  
serum ferritin <12 μg/L 
9 months, 
postpartum  
14 dropouts 
Edinburgh Post-Natal Depressive 
Scale, Ravens Coloured Matrices, 
Perceived Stress Scales 
Murray-Kolb 
and Beard, 
2007 [2] 
152 
American women,  
18–35 years  
160 mg ferrous sulphate, 
containing 60 mg  
elemental iron 
ID = Hb ≥120 g/L and two or more 
other abnormal iron values 
16 weeks  
39 dropouts 
Cognitive Abilities Test IDA = Hb between 105 and  
119 g/L and two or more other 
abnormal iron values 
McClung  
et al., [16] 
219 
Female American 
soldiers, 15–25 years 
100 mg ferrous sulphate, 
15.0 elemental iron ± 0.2 mg 
ID ≥ 2 of the following  
3 indicators: serum ferritin  
<12 μg/L, transferrin saturation  
<16% or red blood cell distribution 
width >15% 
8 weeks  
48 dropouts 
Profile of Mood States 
IDA = ID + Hb of <120 g/L 
Verdon et al., 
2003 [24] 
144 
French females, ID 
only, 18–55 years 
Ferrous sulphate, 80 mg 
elemental iron as pill 
ID = not transparent 
4 weeks  
12 dropouts 
Questionnaire bref  
d’auto-évaluation des dimensions 
dépressive, asthénique et anxieuse 
IDA = Hb <117 g/L 
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Table 1. Cont. 
Vaucher et al., 
2012 [22] 198 
Swiss females, ID only, 
18–50 years 80 mg ferrous sulphate 
ID = Hb ≥120 g/L, and  
ferritin <50 µg/L 
12 weeks  
77 dropouts 
Current and Past  
Psychological Scale 
Lambert et al., 
2002 [23] 121 
Adolescent  
females from New 
Zealand, ID only, 
12.5–17.9 years 
105 mg elemental iron 
ID = Serum ferritin <12 μg/L, 
Hb >120 g/L 8 weeks  
5 dropouts 
Hopkins Verbal Learning Test, 
Stroop Task Visual Search, 
Reading Span Task, Visual  
search task 
IDA = Serum ferritin <12 μg/L, 
Hb <120 g/L 
Devaki et al., 
2009 [20] 120 
Adolescent male and 
female students from 
India, 15–18 years 
Iron (III) hydroxide 
polymaltose complex,  
100 mg elemental iron 
ID boys = Hb ≥115 g/L and 
transferrin saturation <16% 
8 months 
dropouts  
not recorded 
Ravens Progressive Matrices, 
Weschler Adult Intelligence Scale, 
Emotional Quotient  
ID girls = Hb ≥105 g/L and 
transferrin saturation <16% 
IDA boys = Hb <115 g/L and 
transferrin saturation <16% 
IDA girls = Hb <105 g/L and 
transferrin saturation <16% 
Siwek et al., 
2009 [17] 60 
Polish males and 
females with major 
depressive disorder, 
18–55 years 
100–200 mg imipramine 
(antidepressant)  
+ 25 mg zinc 
Serum zinc determined by flame 
atomic absorption spectrometry; 
baseline zinc deficiency  
was unclear 
12 weeks  
9 dropouts 
Hamilton Depression Rating Scale, 
Beck Depression  
Inventory, Clinical Global Impression 
Montgomery—Åsberg Depression 
Rating Scale 
Nowak et al., 
2003 [18] 20 
Polish males and 
females with major 
depressive disorder, 
25–57 years 
clomipramine 125–150 mg, 
amitriptyline 125–150 mg, 
citalopram, 20 mg fluoxetine, 
40–20 mg (all standard 
antidepressant treatment)  
+ 25 mg zinc 
Unclear 12 weeks  6 dropouts 
Hamilton Depression  
Rating Scale, Beck  
Depression Inventory 
Sawada  
and Yokoi,  
2010 [19] 
60 
Japanese females,  
non-anaemic,  
18–21 years 
Multivitamins + 7 mg 
elemental zinc 
Serum zinc determined by 
inductively coupled argon  
plasma-mass spectrometer;  
no other details provided  
on this 
10 weeks 
dropouts  
not recorded 
Profile of Mood States 
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3.8. Evaluation of Validity 
Study validity is reported in Table 2. Randomization procedures were outlined in all but two  
studies [18,20]. The researcher was clearly blinded to intervention in nine studies; the outcome assessor 
was clearly blinded in four studies, and the participants were clearly blinded in nine studies. Masking 
was unclear in one study [21] and did not occur in one study [20]. There were dropouts in nine  
studies [2,15–18,21–24]. Reasons for the dropouts were reported for all but one study [19]. An  
intention-to-treat protocol was used in three studies [15,22,24]. It was unclear how all of the other studies 
dealt with missing data. Four important areas of bias, including selection, performance, detection and 
attrition biases, were informally assessed using a bias hierarchy checklist by Wright, Brand, Dunn  
and Spindler [25]. 
3.9. Results 
Table 3 includes a detailed summary of all of the relevant findings for the included studies. Six studies 
reported increased iron status, as measured by varied markers of iron status in participants treated with 
iron supplements [2,15,16,20–23]. It was unclear in one study whether iron status had increased in the 
iron-treated group [24]. Two zinc studies reported increased serum zinc concentrations, post-treatment 
with zinc supplementation [17,19]; however, this was unclear in the third zinc study [18]. 
3.9.1. Iron and Cognition 
Despite the heterogeneous nature of the included studies, all that looked at the effect of iron status on 
cognition found some form of improvement in cognitive functioning after iron supplementation. Of the 
five studies that assessed the effect of iron supplementation on measures of cognition, two examined the 
effect of iron status on attention at baseline. Murray-Kolb and Beard [2] reported that an increasing level 
of severity of ID was associated with decreased cognitive functioning. Specifically, they found that 
women with ID had a composite baseline score that was significantly worse on tests of attention, learning 
and memory when compared to iron-sufficient participants. Furthermore, the authors reported that 
women with IDA performed significantly worse on tasks of attention and memory in comparison to 
healthy controls. Similarly, Devaki et al. [20] reported that adolescents with ID and IDA had lower mean 
scores on tasks of memory and intellectual ability than healthy controls. 
Attention and Memory 
Of the five studies that assessed the effect of iron supplementation specifically on memory, only one 
found a significant effect. Murray-Kolb and Beard [2] reported that women who received iron 
supplementation and were considered serum ferritin responders, that is women who experienced a 
significant improvement in serum ferritin regardless of whether they initially had ID or IDA, also showed 
significant improvement on measures of attention. Furthermore, they reported that women who showed 
a significant improvement in Hb concentration completed tasks significantly faster than those who did 
not have a significant improvement in Hb. Neither of the studies by Bruner et al. [15] and  
Lambert et al. [23] detected significant improvement on measures of attention upon increasing iron status 
with iron supplementation. 
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Table 2. Validity Characteristics of included studies. 
Study 
Selection Bias or 
Detection Bias 
Performance or 
Detection Bias 
Attrition Bias Controlled Variables Reviewer Notes/Possible Limitations 
Bruner et al., 
1996 [16] 
Randomization clear, 
double-blinded design 
Researchers and 
participants blinded  
to allocation 
Not all randomized included in 
outcomes; dropouts and 
reasons for dropouts reported 
Additional vitamins  
and minerals 
All participants had ID. There was no 
measurement of baseline differences 
between iron-sufficient and ID 
adolescents. Serum ferritin was a marker 
of iron status. Statistical analysis was by 
group assignment, rather than  
ferritin response. 
Beard et al., 
2005 [21] 
Randomization clear, 
double-blinded design 
Participants unaware  
of group allocation 
Intention-to-treat protocol 
utilized to deal with missing 
data; dropouts reported; 
however, reasons for dropouts 
not reported 
Age, socioeconomic status, 
income, education, 
nutritional intakes 
Staff members administered 
supplementations at health clinics with 
instructions for the mothers on when to 
take and when to return, etc. 
Standardized outcome measures  
were used. 
Murray-Kolb 
and Beard,  
2007 [2] 
Randomization clear, 
double-blind  
placebo-controlled design 
One researcher knew  
the group allocation; 
outcome assessors, as 
well as participants  
were blinded to  
group allocation 
Not all of those randomized 
included in outcomes;  
dropout rates reported; 
however, reasons for dropouts 
not reported 
Socioeconomic status, grade 
point average, level of 
physical activity and other 
demographics; 
other vitamins/minerals; 
inflammation, contraception 
and menstrual cycle; 
intellectual ability (IQ) was 
used as a covariate 
Standardized and validated measures of 
were cognition used. High reliability. 
Analysis was completed on women who 
were classified as ferritin responders or 
non-responders. Determination of the 
relationship between changes in iron 
status and changes in cognition.  
16 weeks used to allow more time for 
brain iron concentrations to replenish. 
  
 
Nutrients 2014, 6 5127 
 
Table 2. Cont. 
McClung et al., 
2009 [16] 
Randomization reported, 
double-blind,  
placebo-controlled design 
Researchers, outcome 
assessors and 
participants all blinded 
to allocation 
Unclear if all of those 
randomized included in 
outcomes; dropout rates and 
reasons for dropouts reported 
 
Compliance monitored and assessed as a 
confounding variable. Research assistants 
administered capsules to participants each 
day. Treatment occurred on the 
background of battle combat training. 
Randomization procedures were  
not described. 
Verdon et al., 
2003 [24] 
Randomization clear, 
double-blind design 
Researchers, outcome 
assessors and participants 
blind to allocation 
Intention-to-treat protocol 
completed to deal with missing 
data; dropout rates recorded and 
reasons for dropout recorded 
Other disorders that could 
explain fatigue 
Intervention period was relatively shorter 
than other included studies. A validated  
self-administered questionnaire was 
used, although fatigue was assessed on a 
visual analogue scale. Adherence to 
treatment was monitored by an electronic 
device that recorded the date and time 
that the pill container was opened 
Vaucher et al., 
2012 [22] 
Multi-centre study, 
randomization clear, 
double-blind,  
placebo-controlled design 
Researchers, outcome 
assessors and participants 
blinded to allocation 
Intention-to-treat protocol 
completed to deal with  
missing data 
 
A validated self-administered questionnaire 
used. Intention-to-treat analysis was used, 
and attrition and compliance were less of 
an issue. Dropout rates were not reported 
Lambert et al., 
2002 [23] 
Randomization occurred, 
but allocation procedures 
not described 
Researcher and 
participants blinded  
to allocation 
Unclear if randomized 
participants included in 
outcomes/dropout rates 
reported/reasons for  
dropouts reported 
 
Standardized and validated outcome  
measures were used. 
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Table 2. Cont. 
Devaki et al., 
2009 [20] 
No randomization 
described 
No blinding  
methods described 
Unclear if randomized 
participants included in 
outcomes; dropout rates and 
reasons for dropout reported 
 
Compliance was monitored as supplements 
were administered by a supervisor at breakfast 
and lunch. Potential for performance, selection 
and detection bias. 
Siwek et al., 
2009 [17] 
Randomization clear 
Researchers and 
participants blinded  
to allocation 
  Outpatient sample. 
Nowak et al., 
2003 [18] 
Randomization described 
Researchers and 
participants blinded  
to allocation 
Unclear if randomized 
participants included in 
outcome; dropout rates 
reported however reasons for 
dropout not reported 
 
Clinical sample, so it is difficult to generalize 
to wider population. Standardized and 
validated measures of depressive symptoms 
were used. Allocation procedures were  
not described. 
Sawada and 
Yokoi, 2010 [19] 
Randomization clear,  
A double-blind,  
double-blinded,  
placebo-controlled design 
Researchers and 
participants blinded  
to allocation 
Information around dropout 
rates and missing data  
was not reported 
Age, height, body 
mass, body weight 
Pilot study, first of its kind. There are missing 
data and information around how this was dealt 
with. Treatment was possibly confounded by the 
use of multivitamins, alongside zinc 
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Table 3. Summary of relevant results. HVLT, Hopkins Verbal Learning Test; MCV, mean corpuscular volume. 
1: Iron 
Study 
Dependent 
Variable 
Domains Statistical Analysis 
Changes in  
Iron/Zinc Status 
Findings 
Bruner et al., 
1996 [15] 
Cognition 
Attention: Assessed using 
Brief Test of Attention 
(BTA), Symbol Digit 
Modalities Test (SDMT) 
and Visual Search and 
Attention Test (VSAT). 
Memory: multicomponent 
test, Hopkins Verbal 
Learning Test (HVLT). 
Learning: multicomponent 
test, HVLT 
Intention-to-treat analysis; 
multiple linear regression, 
assessment of post iron 
treatment cognitive scores; 
analysis of variance 
(ANOVA), assessed HVLT 
learning curve 
Iron girls: significantly 
higher serum ferritin 
concentration (18.2  
(SD 12.6) vs. 3.5 (6.6) µg/L,  
p < 0.001) and higher mean 
Hb concentration (135 (8.0) 
vs. 127 (7.0) g/L, p < 0.001) 
No significant effect on attention were found. 
Significant improvement on total recall scores of 
HVLT for girls who took iron treatment, compared to 
control group (p < 0.02). No significant differences 
were found between delayed recall and recognition. 
Learning: All participants recalled more words after 
each trial (F = 273.7), p < 0.001), although no 
significant differences were found between groups.  
Despite this, participants who took iron treatment 
performed better compared to the control group  
(F = 6.3, p < 0.02). 
Beard et al., 
2005 [21] 
Cognition 
Intellectual abilities: 
Raven’s Coloured 
Progressive Matrices 
(RPM). Memory: Digit 
Symbol Test 
Repeated measures ANOVA; 
Pearson’s correlation, strength 
of association between 
variables 
IDA iron group: Significant 
improvement in Hb 
transferrin saturation 
(TSAT) and serum ferritin 
(Ft) values. IDA placebo: 
Also significant increase in 
Hb, reflecting natural state 
of iron status restoration 
postpartum. Iron sufficient: 
No change in haematology 
Iron treatment effected significant improvement on 
RPMs and Digit Symbol scores. Iron-treated 
mother’s scores were almost identical to  
non-anaemic mothers at 9 months.  
An association was found between 
—RPM scores and Hb, 10 weeks 
—Digit symbol test and MCV at 9 months 
Emotions 
(postpartum 
depression) 
Postpartum depression: 
Edinburgh Postnatal 
Depression Scale (EPDS) 
Repeated Measures ANOVA; 
Pearson’s Correlation 
 
Results of EPDS were unclear. Pearson’s correlation 
found that scores on the EPDS Hb and MCV. 
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Table 3. Cont. 
Murray-Kolb 
and Beard, 
2007 [2] 
Cognition 
IQ: Shipley Institute of 
Living Scale (20), 
Cognitive Abilities test 
(CAT) measuring 3 
domains. Attention: 
Reaction Time Task. 
Memory: Reaction Time 
task (short-term memory 
(STM)), Probe Recall Task 
(recognition), Sternberg 
Memory Search Task 
(STM, retrieval and 
executive functioning). 
Learning: CAT 
ANCOVA, assessed 
differences between groups 
with IQ as a covariate; 
repeated-measures ANOVA, 
assessed change in cognitive 
variables over time 
Iron-treated participants 
were found to have 
significantly improved iron 
status. Significant increases 
occurred in ID iron 
treatment and IDA iron 
treatment groups for ferritin 
(p < 0.001 and p < 0.01, 
respectively) and body iron 
(p < 0.0001 and p < 0.01, 
respectively) The IDA  
iron-treated participants also 
had a significant increase in 
Hb (p < 0.0001), haematocrit  
(p < 0.001) and transferrin 
saturation (p = 0.018). 
Cross-sectional baseline comparisons: 
Attention: Composite score significantly lower in 
IDA group, between iron sufficient and ID  
(p = 0.008; p = 0.003, respectively). Performance in 
attention significantly better than IDA group, in 
control group and iron-deficient groups (p = 0.047 
and 0.008, respectively). Memory: Composite scores 
show that iron-sufficient and ID groups scored equally 
well and significantly better than IDA (p < 0.001). 
Performance in this domain showed the same pattern. 
Learning: Composite score on the learning domain 
showed that iron-sufficient group scored better than ID 
group, and there was a significant difference between  
iron-sufficient and IDA group (p = 0.013) and ID and 
IDA group (p = 0.042). 
Longitudinal analysis: 
Significant improvement in serum ferritin (n = 66) 
was related to improvements in the attention and 
learning and memory domains, 5-/7-times, 
respectively, in women that were non-responders  
(n = 66) (p < 0.001). No significant correlation 
between the size of ferritin change and the cognitive 
improvement. Women who had significant change in 
Hb concentration (n = 33) completed the attention and 
memory tasks significantly faster than Hb  
non-responders (n = 80) (p < 0.001). 
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Table 3. Cont. 
McClung et al., 
2009 [16] 
Mood and 
physical 
performance 
General mood: Profile of 
Mood State (POMS) 
Two-way repeated measures 
ANOVA, treatment and  
time effects 
Participation in 8-wk battle 
combat training had effects on 
iron status, as shown by elevation 
(p < 0.05) of Hb, red blood cell 
distribution width and soluble 
transferrin receptor (sTfR) in 
both placebo and iron-treated 
groups. Serum ferritin was 
diminished (p < 0.05) in placebo, 
but not iron-treated groups. 
Group x Time interaction for vigour on the 
POMS: Iron supplementation had a significant 
effect on vigour, after Battle CombatTraining 
(BCT). After stratification by iron status at the 
beginning of BCT, the positive effects of time 
on mood stayed significant (p < 0.05) for all 
indicators, except anger, in the  
iron-deficient group 
Verdon et al., 
2003 [24] 
Depression, 
anxiety and 
fatigue 
Depressive and anxiety 
symptoms: Questionnaire 
bref d’auto-évaluation des 
dimensions dépressive, 
asthénique et anxieuse 
Intention-to-treat protocol χ2 
and linear regression Unclear 
The iron group showed the largest decrease in 
cumulative −4.6 (7.5) score for fatigue  
(−7.5 (8.0)), a difference of 3.0 points, 0.3 to 
5.6, p = 0.03. Scores for depression were not 
significant between groups. Depression was not 
associated with any markers of iron status 
Lambert et al., 
2002 [23] Cognition 
Verbal Working Memory, 
free recall: Hopkins 
Verbal Learning Test. 
Attention: Stroop Task. 
Processing speed and 
attention: Visual Search. 
Working memory: Reading 
Span Task. 
Multiple  
regression analysis 
Ferritin level was increased for 
both placebo (t (58) = 3.73,  
p < 0.001) and iron group  
(t (56) = 9.16, p < 0.001). It was 
found that the extent of increase 
was larger in the iron group. A 
significant decrease in Hb 
concentration was found in the 
placebo group pre-/post-treatment 
(t (56) = 4.09, p < 0.001), and there 
was no change in Hb level for iron 
groups pre-/post-treatment  
(t (56) = 1.41, not significant). 
Hopkins Verbal Learning Test: For the iron 
group, significant improvement in recall of 
words from baseline to post-treatment  
(t (56) = 2.40, p = 0.01) in the second half list, 
but no significant relationship between iron 
treatment and the first half of the list. A 
significant relationship between Hb change and 
post-treatment performance on recall for the iron 
treatment group, second half of the list only  
(p < 0.004). Reading Span Test: Multiple 
regression found a significant relationship 
between change in serum ferritin and reading 
span (p < 0.01). Stroop Task:  
No relationship found between performance on 
this task with changed iron status or 
supplementation. Visual Search Task.  
No treatment x testing interaction found. 
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Table 3. Cont. 
Devaki et al., 
2009 [20] 
Cognition 
and Emotion 
(mood) 
STM: recall a list of 6 digit 
numbers, after interpolated 
activity, asked to recall 
(not as in Wechsler 
Intelligence Scale 
(WAIS)). Long-term 
memory (LTM): recited 
the stimulus number, 
presented four times and 
then asked to recall one h 
of interpolated activity 
(not as in WAIS). IQ: 
Ravens Progressive 
Matrices (RPM). WAIS. 
Affective behaviour:  
Emotional Quotient. 
2 × 2 ANOVA with duration 
as one factor and study group 
as another 
Iron-sufficient, supplement group, 
ID and IDA groups showed 
significant increases in Hb, 
transferrin saturation (TS) and 
serum ferritin 8 months  
post-treatment (p < 0.01).  
Iron-sufficient, placebo group 
showed no increase in iron status. 
Iron supplementation groups showed 
improvements in mean scores of STM, LTM 
WAIS and RPM, at four- and eight-month 
follow up, which also reflected changes in 
haematological parameters. Changes in 
cognitive scores were much higher in the  
iron-deficient and iron-deficient anaemic group, 
compared to iron-sufficient, supplement group. 
No significant change in Emotion Quotient 
(EQ) score was seen for any group. 
Vaucher et al., 
2012 [22] 
Primary 
Fatigue: 
Secondary: 
Mood 
Fatigue and depressive 
symptoms: Current and 
Past Psychological Scale. 
Fatigue: Multidimensional 
Assessment of Fatigue 
score; self-reported health 
questionnaire, Global 
Fatigue Index and 
Severity. 
Intention-to-treat analysis 
After 6 weeks of iron treatment, 
significant effects on markers of 
iron status were found for  
iron-supplemented groups.  
Hb: (3 g/L; p = 0.001).  
Ferritin: (6.8 μg/L; p = 0.01).  
MCV: (1.2 fL; p = 0.01).  
sTfR: (−0.4 mg/L; p < 0.001) 
transferrin saturation (6.6%;  
p < 0.001). Similar effects were 
seen after Week 12. 
Patients receiving iron supplement had a 3.5 
point improvement (95% CI) in their fatigue 
score in current and past psychological scale 
compared to those in placebo group. Iron 
treatment had a significant effect on the global 
fatigue index from the Multidimensional 
Assessment of Fatigue Scale (p = 0.03) and its 
severity index (p = 0.03). Iron was not found to 
have a significant effect on anxiety or 
depression scores in this study. 
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Table 3. Cont. 
 2: Zinc 
Study Dependent Variable Domains Statistical Analysis 
Changes in  
Iron/Zinc Status Findings 
Siwek et al., 
2009 [17] Depression 
Depressive Index scores 
on Clinical Global 
Impression (CGI), 
Montgomery-Åsberg 
Depression Rating Scale 
(MADRS), Hamilton 
Depression Rating Scale 
(HDRS), Beck Depression 
Inventory (BDI). 
Remission of depression 
was defined by a score of 
“very much” on CGI, plus 
scores of ≤7 on HDRS, 
≤10 on MADRS or ≤9  
on BDI. 
Linear model, mixed-design 
ANOVA, with repeated factor 
being test number, and between 
factors being treatment, 
antidepressant and  
treatment resistance.  
A non-treatment-resistant group 
and a treatment-resistant  
group formed. 
Zinc-supplemented groups had a 
significant increase in serum zinc 
levels at Weeks 6 and 12.  
Non-zinc-supplemented groups saw 
an increase of zinc at Week 12. 
Treatment-resistant groups 
demonstrated lower levels of zinc 
than treatment- and  
non-treatment-resistant groups. 
A significant negative correlation between zinc 
levels and MADRS scores at Week 12 was 
found, when either all (p < 0.0001) or zinc 
supplemented patients were taken into  
the analysis 
Nowak et al., 
2003 [18] Depression 
Depression Index: HDRS 
and BDI. 
Group differences were 
assessed using t-test and 
multiple ANOVA with two 
between-subjects factors 
(placebo vs. zinc treatment) 
Unclear 
Scores of the HDRS were significantly reduced 
over time: F (3, 28) = 5.091; p < 0.001, placebo, 
and F (3, 20) = 29.578 p < 0.001, zinc group. The 
group effect (F (1, 48) = 4.275, p = 0.049) and 
time effect (F (1, 48) = 21.683; p < 0.001) were 
statistically significant. There was no significant 
interaction effect. Zinc improved this reduction at 
Weeks 6 and 12, compared to treatment (ca. 
55%). Zinc supplementation significantly 
improved the reduction in BDI scores at Week 12, 
compared to placebo (by 40%). 
Sawada and 
Yokoi, 2010 
[19] 
Depression 
Somatic symptoms and 
mood feelings, like 
anxiety, sensitivity, anger 
and tension: Profile of 
Mood State (POMS) and 
Cornell Medical  
Index (CMI). 
Data were analysed with 
Wilcoxon’s signed-rank test 
Neither intervention showed a 
significant change in serum 
ferritin or Hb concentration. 
Multivitamin (MV) + zinc 
significantly increased serum zinc 
concentration, whereas MV alone 
did not. 
Women who took multivitamins with zinc 
showed a significant decrease in anger-hostility 
and depression-dejection scores on the POMS. 
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All five studies assessing the effect of iron supplementation on memory found significant 
improvements on some aspects of memory regardless of whether the participants had been classified as 
having ID or IDA at the beginning of the clinical trial. Differences in dose ranged between 100 mg 
elemental iron once per day [14] to 130 mg elemental iron twice daily [7]. Further information on dosage 
can be found in Table 1. Murray-Kolb and Beard [2] administered a supplement including 160 mg 
ferrous sulphate with 60 mg of elemental iron once daily. Four studies found improvement on tasks of 
working memory after treatment with iron supplementation [2,15,21,23]. Additionally, Devaki et al. [20] 
reported a significant improvement on tasks of STM and LTM after iron intervention. 
Both Bruner et al. [15] and Lambert et al. [23] reported significant improvements on verbal working 
memory post-iron treatment, even in participants with ID. Murray-Kolb and Beard [2] found no 
significant differences between iron ID participants and iron-sufficient controls on measures of memory; 
however, participants who were serum ferritin responders did significantly improve on these tasks. 
Lambert et al. [23] also reported a relationship between changes in Hb concentration and 
improvement in recall of recently heard words, changes in serum ferritin and improvement in reading 
span task and post-treatment ferritin level and post-treatment reading-span performance. Similarly, 
Beard et al. [21] reported significant correlations between mean corpuscular volume (MCV) and 
performance on the digit symbols task at nine months postpartum. 
Learning 
Two studies examined the effect of iron supplementation on learning. One study found an overall 
effect of learning on the Hopkins Verbal Learning Test (HVLT) scores between treatment and placebo 
group in groups of females with ID in the absence of anaemia [15]. Bruner et al. [15] noted that both 
iron and placebo groups recalled more words on the HVLT recall task after each successive trial; 
however, there was no significant difference between these groups. Although they found that both groups 
did better after intervention, it was noted that girls who received iron supplementation recalled more 
words on each trial than girls who received the placebo. Murray-Kolb and Beard [2] reported that serum 
ferritin responders showed significant improvement in their learning abilities. They reported that 
improvements in learning for ferritin responders were five- to seven-times greater than the improvement 
in women who did not have a significant increase in serum ferritin. 
Intellectual Ability 
Beard et al. [21] found significant improvements on Ravens Progressive Matrices (RPM) scores, for 
mothers receiving iron supplementation, and they noted that their scores were almost identical to those 
of control non-anaemic mothers at the end of the treatment period. They also report that anaemic mothers 
who did not receive iron had no change in cognitive performance over time. Furthermore, they noted a 
correlation between increased Hb concentration at 10 weeks and improved scores on the RPM. Similarly, 
Devaki et al. [20] observed that iron supplementation in adolescents with either ID or IDA was 
associated with significant improvement in intellectual ability in comparison to healthy controls 
receiving iron or healthy controls with placebo. 
  
 
Nutrients 2014, 6 5135 
 
3.9.2. Iron and Mood 
Studies investigating whether increasing iron status effects changes on parameters of mood were 
mixed, and those presented within this literature review should be interpreted with caution. Two studies 
found no association between changes in iron status and depressive symptoms or other mood aspects, 
including anxiety [22,24]. McClung et al. [16] reported that battle combat training resulted in significant 
improvement in mood state over time on all subscales of the Profile of Mood State (POMS) and the total 
score for both groups. Despite this, the only subscale in which there was a significant group by time 
interaction was for vigour, indicating that this was the only subscale on which iron supplementation had 
any effect [16]. Alternatively, Beard et al. [21] reported finding a 25% improvement in previously  
iron-deficient mothers’ depressive scale following an iron supplement compared with a placebo-
controlled group. Multivariate analysis suggested a strong link between the Edinburgh Post-Natal 
Depression Scale (EPNDS) and markers of iron status, specifically mean corpuscular volume and Hb 
concentration [21]. 
3.9.3. Zinc and Depression 
Two studies assessed the efficacy of zinc supplementation as an adjunct to antidepressant treatment 
for depression. Nowak et al. [18] found statistically significant group effects (treatment vs. placebo) and 
time effects (pre-treatment vs. post treatment) for zinc supplementation as an adjunct to antidepressant 
therapy. It was observed that zinc supplementation significantly augmented the reduction in Hamilton 
Depression Rating Scale score at Week 12 of treatment [18]. Similarly, Siwek et al. [17] found the zinc 
supplementation as an adjunct to tricyclic antidepressant treatment significantly reduced depressive 
symptoms measured by the Montgomery–Åsberg depression rating scale (MDRAS). They reported this 
result in participants who were deemed treatment resistant. The same pattern was not observed in 
depressed individuals who were treatment responsive. 
Only one study was found that examined the effect of zinc supplementation on mood states. Sawada 
and Yokoi [19] discovered that individuals who were provided with multivitamin (A, D, B1, B2, B6, 
B12, niacin and folic acid) supplements containing 7 mg added of elemental zinc significantly decreased 
scores on anger-hostility and depression-dejection scales on the POMS (p < 0.05). 
4. Discussion 
The current systematic literature review found five studies that suggested reduced iron status, 
regardless of whether it is ID or IDA, has a detrimental impact on cognitive function in pre-menopausal 
women. All five studies found that increasing iron through supplementation had a positive influence on 
the performance on tasks measuring certain aspects of memory. Four of these studies found significant 
improvements on tasks of working memory [2,15,21,23], while one noted improvements on tasks of 
STM and LTM [20]. Only one of the five studies examining the effects of increasing iron status on 
cognitive functioning found a positive effect on attention [2]. Furthermore, some improvement was 
found in learning ability in women who were serum ferritin responders, but again, only in one study [2]. 
In addition, two studies found significant improvements in intellectual ability [20,21]. The results of the 
current literature review suggest that some, but not all, aspects of cognitive function are impacted by 
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lowered iron status. Memory, particularly working memory and intellectual ability, may be affected by 
states of iron insufficiency and are potentially improved as iron status is improved. Furthermore, 
conclusions about the influence of low iron on attention and learning in premenopausal women cannot 
be made based on this review alone, and further research is required to fully understand these results [2]. 
These findings are somewhat in contrast to those reported by a meta-analysis on a similar topic. 
Falkingham et al. [26] reported no evidence to suggest any overall effect on memory, psychomotor skills 
or scholastic achievement in either older children or pre-menopausal women, but did find effects of iron 
supplementation on aspects of attention and intelligence. In a recent review, Murray-Kolb [27] discussed 
a number of intervention studies on pre-menopausal women and reported on five that found 
improvements on differing measures of memory after iron supplementation. Furthermore, Murray-Kolb 
discussed a number of observational studies and reported a correlation between memory, attention, 
learning and spatial ability. There is still a relative paucity of research in this area highlighting the need 
for carefully-designed, randomized controlled trials. 
The effect of iron supplementation and its role in improving mood states is not clear, and the 
interpretation of studies to date is hindered by the range of instruments used to measure mood. Two of 
the four studies that looked at the effect of increasing iron on mood found no significant improvement 
of depressive symptoms after iron supplementation, despite a significant increase in iron status [22,24]. 
However, these studies were only exploring the effect of iron supplementation on depressive symptoms 
as a secondary outcome, and the inclusion of more comprehensive depressive scales may have yielded 
different results. On the other hand, a number of previous studies have observed a relationship between 
low iron status and mood, indicating a potential role for iron in the development of mild depressive 
symptoms [28,29]. The study by Beard et al. [21] reported a significant improvement in depressive 
symptoms after iron supplementation. The participants of this study did not have a diagnosis of MDD, 
and the researchers were looking specifically at the risks of ID in developing postpartum depression. 
Nonetheless, the results of this study appear to indicate that women with IDA may be susceptible to 
developing postpartum depression and that treatment with iron can reverse these symptoms.  
McClung et al. [16] found a significant positive effect over time of iron supplementation on scores on 
the POMS for the subscale vigour, but failed to find any similar effect for the depression subscale. While 
results are mixed, previous research suggests that there is a relationship between low iron status and 
mood. For example, Vahdat Shariatpanaahi et al. [28] report finding that serum ferritin levels were 
significantly lower (11 μg/L) in individuals with depression in comparison to healthy controls. 
Furthermore, they reported that the incidence of ID was higher in depressed individuals by 15%. 
Similarly, a study on postpartum depression discovered a relationship between lowered Hb concentration 
and depressive symptoms in comparison to mothers with a normal Hb concentration postpartum [29]. 
This area of research warrants well-designed randomized controlled trials with a large population sample 
utilizing standardized and valid measures of depressive symptoms. 
Clinical intervention trials looking at the effect of zinc supplementation on aspects of mood are 
limited, and no intervention trials looking at the effect of zinc supplementation on improving cognition 
were found using the current search criteria. Results for zinc studies found in this review are similar to 
that of Lai et al. [30], as little research in this area has been conducted since then. Zinc has been found 
to be effective in the treatment of depressive symptoms, both as an adjunct to traditional antidepressant 
medication and as a stand-alone treatment. The findings by Sawada and Yokoi [19] are preliminary and 
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need to be interpreted with caution; however, they do suggest a role for zinc in the treatment of mild 
depressive symptoms in the absence of a confounding antidepressant treatment. That being said, both 
the treatment and placebo groups were provided with additional multivitamins, so intervention  
studies using only zinc as a treatment are required to clearly elucidate the role of zinc in the treatment  
of depression. 
While no studies were found looking at the association between low zinc status and cognitive 
function, there is evidence to suggest that there is a potential role for zinc in improving aspects of 
cognitive ability [31–33]. For example, Keller, Chu and Coffield [31] observed that pregnant women 
with zinc deficiency performed significantly worse on the Raven’s Progressive Matrices than those 
without zinc deficiency. Furthermore, Maylor et al. [34] in a randomized controlled trial on cognitive 
function in healthy middle-aged and older adults (>70) found a significant positive effect of zinc 
supplementation on spatial working memory, but a detrimental effect on one measure of attention. As 
with all of the variables included within this review, further well-designed randomized controlled trials 
in adults are warranted to better understand the causal relationship between zinc and cognition. 
Heterogeneity among the included studies with regard to population and outcome measures used 
make it difficult to compare the results completely. Only one study controlled for the potential effect of 
inflammation, as measured by C-reactive protein, on iron status in participants [2]. This is a useful 
variable to control for, as inflammation caused by chronic disease (e.g., tuberculosis or endocarditis), 
autoimmune disease (e.g., Crohn’s disease), obesity or exercise can negatively impact iron status and in 
itself can result in ID [35]. Furthermore, Murray-Kolb and Beard [2] were the only researchers to use IQ 
as a covariate when looking at learning ability and intellectual functioning. Despite this, most studies 
matched their participants for socioeconomic status, education, age and physical activity, and most of 
the studies had procedures to monitor compliance. Generally, all studies were at low risk of selection, 
performance, detection and attrition biases, as randomization or allocation procedures were made 
explicit; blinding after allocation was explicit and, for the most part, attrition rates were reported. 
However, it should be noted that the study by Devaki et al. [20] is at risk of selection, performance and 
detection biases, because randomization of participants did not occur, nor were the investigators or subjects 
blinded to the group in which they were. While all studies included control groups, Bruner et al. [15] split 
their ID participants into control or treatment groups and, thus, were unable to measure baseline 
differences between normal status and iron-deficient adolescents. Devaki et al. [20] had a supplemented 
control group; however, they neglected to have iron-deficient or anaemic participants take a placebo. 
Therefore, their study was not truly placebo controlled. 
The current search yielded no results looking at increasing zinc and its effects on cognitive 
functioning and limited results looking at zinc supplementation and its effects on depression. Secondly, 
no studies were found that used dietary methods to increase iron or zinc, and lastly, there was limited 
literature looking specifically at women of childbearing age. As a consequence, the search terms for this 
review were broadened to include oral iron supplementation, as well as male participants. This means 
that the results of the current review cannot be generalized specifically to pre-menopausal women, nor 
can it comment on the effectiveness of increasing dietary iron and zinc on improved mood or cognitive 
functioning, which was the original intended purpose of this review. Thus, studies investigating the 
relationship between dietary iron and zinc on markers of mood and cognition, and whole of diet 
interventions aimed at improving neuropsychological functioning are required. 
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5. Conclusions 
The current review has explored the effect of increasing elemental iron, or zinc, on aspects of mood 
and cognition. Some evidence has been found to suggest a positive effect of increasing iron status on 
cognitive functioning. It also seems that this positive effect occurs regardless of whether the participant 
was initially iron insufficient or iron deficient with anaemia. Results are mixed as to whether iron 
deficiency impacts on general mood; however, further research in this area is warranted. The current 
review also found some evidence to suggest that increasing zinc may have a positive impact on mood. 
Further study in the area, utilizing well-designed randomized controlled designs, is needed in order to 
strengthen the evidence suggesting a causal relationship. Given the risk posed for women of child 
bearing age for iron and zinc deficiencies, it would be useful to have further research specific to this 
population group. Furthermore, research exploring the effectiveness of using dietary approaches to 
increasing iron and zinc in pre-menopausal women to improve cognitive functioning and mood  
states is warranted. 
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Appendix 
Appendix 1. Initial Search Strategies 
From Proquest Health and Medical complete search. 
Iron/mood/cognition: (ab((iron) AND (deficien* OR status OR intake OR dietary OR nutrition*)) 
AND peer(yes)) AND ((su((mood) OR (depress*) OR (affect*)) AND peer(yes)) OR (cognit* AND 
peer(yes))) AND (su((wom?n) OR (“female*”)) AND peer(yes)) 
Zinc/mood/cognition: ((all(“zinc deficien*” OR “low zinc” OR “zinc store*” OR “zinc status” OR 
“decree* zinc” OR “deplete* zinc” OR “dietary intake of zinc”) AND peer(yes)) AND (ab(mood OR 
affect* OR depress*) AND peer(yes))) OR ((all(“zinc deficien*” OR “low zinc” OR “zinc store*” OR 
“zinc status” OR “decree* zinc” OR “deplete* zinc” OR “dietary intake of zinc”) AND peer(yes)) AND 
(ab(Cognit*) AND peer(yes))) 
Appendix 2. Refined Search Strategies 
From Proquest Health and Medical Complete search. 
Iron/mood/cognition/women: (ab((iron) AND (deficien* OR status OR intake OR dietary OR 
nutrition*)) AND peer(yes)) AND ((su((mood) OR (depress*) OR (affect*)) AND peer(yes)) OR 
(cognit* AND peer(yes))) AND (su((wom?n) OR (“female*”)) AND peer(yes)) 
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Zinc/mood/cognition/women: ((zinc) AND (deficien* OR status OR intake OR dietary)) AND 
(su((mood) OR (depress*) OR (affect*)) OR cognit*) AND su((wom?n) OR (“female*”)) 
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